1221 related articles for article (PubMed ID: 28446615)
1. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT; Behera M; Wu H; McCausland M; Chen Z; Zhang C; Khuri FR; Owonikoko TK; Ahmed R; Ramalingam SS
Proc Natl Acad Sci U S A; 2017 May; 114(19):4993-4998. PubMed ID: 28446615
[TBL] [Abstract][Full Text] [Related]
2. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
3. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
5. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
6. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
7. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
8. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes in circulating PD-1
Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
[TBL] [Abstract][Full Text] [Related]
10. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.
Rutkowski J; Cyman M; Ślebioda T; Bemben K; Rutkowska A; Gruchała M; Kmieć Z; Pliszka A; Zaucha R
Cell Immunol; 2017 Dec; 322():26-33. PubMed ID: 28939130
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X
Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861
[TBL] [Abstract][Full Text] [Related]
13. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
14. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
Kamphorst AO; Wieland A; Nasti T; Yang S; Zhang R; Barber DL; Konieczny BT; Daugherty CZ; Koenig L; Yu K; Sica GL; Sharpe AH; Freeman GJ; Blazar BR; Turka LA; Owonikoko TK; Pillai RN; Ramalingam SS; Araki K; Ahmed R
Science; 2017 Mar; 355(6332):1423-1427. PubMed ID: 28280249
[TBL] [Abstract][Full Text] [Related]
15. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract][Full Text] [Related]
16. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Daud AI; Loo K; Pauli ML; Sanchez-Rodriguez R; Sandoval PM; Taravati K; Tsai K; Nosrati A; Nardo L; Alvarado MD; Algazi AP; Pampaloni MH; Lobach IV; Hwang J; Pierce RH; Gratz IK; Krummel MF; Rosenblum MD
J Clin Invest; 2016 Sep; 126(9):3447-52. PubMed ID: 27525433
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
19. The First-week Proliferative Response of Peripheral Blood PD-1
Kim KH; Cho J; Ku BM; Koh J; Sun JM; Lee SH; Ahn JS; Cheon J; Min YJ; Park SH; Park K; Ahn MJ; Shin EC
Clin Cancer Res; 2019 Apr; 25(7):2144-2154. PubMed ID: 30647082
[TBL] [Abstract][Full Text] [Related]
20. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
[Next] [New Search]
